UVLRX-THERAPEUTICS
UVLrx Therapeutics ™ is pleased to present its intravenous light treatment system at the 5th Annual Pro-Aging Europe Congress , a four-day event highlighting medical therapies that reduce, slow down and even reverse the aging process. Beginning on November 19th , this year’s Congress will attract hundreds of the world’s leading anti-aging and aesthetics physicians.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151110007124/en/
Following the company’s recent CE Mark clearance for the UVLrx Station™ Model UVL1500, UVLrx Therapeutics™ will highlight the clinically-proven benefits of light wavelengths utilized by the UVLrx Treatment System. The UVLrx Station™ Model UVL1500 offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical issues. Using the company’s patent-pending Dry Light Adapter™ and a standard IV catheter, the device treats blood intravenously, thus eliminating the need for removal of blood from the body.
Among UVLrx Therapeutics Model UVL1500’s eight indications for use in the EU, the UVLrx™ Treatment System significantly reduces inflammation, the root cause of accelerated aging. It also significantly reduces pain and accelerates post surgical healing, two critical factors associated with many aesthetic procedures.
“We are excited to share our technology at the Congress this year and demonstrate in person how we can contribute to patient care within the field of aesthetics and aging,” says Michael Harter, CEO and president of UVLrx™. “By exhibiting at this event, under the supervision of Dr. Thierry Hertoghe , we have the opportunity to treat the world’s leading anti-aging physicians, which will help them understand firsthand UVLrx’s potential within this growing medical field.”
Ultraviolet Blood Irradiation (UBI) has been used for over a century to treat bacterial and viral infections and was awarded a Nobel Prize for treating lupus in 1903. Routinely used in hospitals around the world, this form of light therapy fell out of prominence in the U.S. with the advent of antibiotics in the 1950s. With the recent expansion in drug-resistant infections, blood irradiation offers significant advantages to pharmaceutical therapies. Furthermore, UVLrx’s intravenous system is superior to existing ultraviolet blood irradiation (UBI) in that it does not require removal of blood from the body.
To learn more, please visit http://uvlrx.com/ and http://bit.ly/1RLN2zb . Be sure to attend UVLrx’s Therapeutic Workshop at the Pro-Aging Congress featuring Chief Scientist Ryan Maloney on Friday, November 20th from 7:00 p.m. to 9:30 p.m.
About UVLrx Therapeutics
Based in Oldsmar, Florida, UVLrx
Therapeutics is dedicated to evidence-based medicine in the field of
light therapy and offers the first intravenous, concurrent delivery of
ultraviolet-A (UVA) and multiple visible light wavelengths for treating
a variety of medical issues. In addition to two Nobel Prizes and
NASA-backed research, hundreds of international clinical trials have
verified the health benefits of UV and other wavelengths of light
utilized in the UVLrx™ Treatment System. For more information, please
visit www.uvlrx.com
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151110007124/en/
Contact:
Press:
Crier Communications
JP Lincoln, 310-274-1072 ext. 201
jp@crierpr.com
or
Business:
UVLrx
Therapeutics
Rowland Hanson
Rowland@UVLrx.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aptiv Powers Intelligent Edge Applications From Automotive to Robotics at CES 20265.1.2026 07:01:00 CET | Press release
Showcase Features Aptiv Technologies Enabling Intelligent Cars, Commercial Vehicles, Robots, and Other Mission Critical ApplicationsImmersive Demos Highlight End-to-End AI for Autonomy, Personalized User Experience and Extensive Connectivity Aptiv PLC (NYSE: APTV),a global industrial technology company, will showcase at CES 2026 how its intelligent edge solutions enable devices to sense, think, and act in real time—while continuously optimizing performance throughout their lifecycle. This approach brings advanced computing and artificial intelligence closer to where data is generated, unlocking AI-driven solutions for transportation, robotics, aerospace, and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260104888341/en/ Aptiv Powers the Intelligent Edge from Automotive to Robotics at CES 2026 By processing data locally at the edge, rather than relying solely on centralized cloud systems, Aptiv’s solutions enable fas
Belkin styrker beskyttelsen af hverdagsenheder med en ny serie skærmbeskyttere og et Wear & Tear-program4.1.2026 18:00:00 CET | Pressemeddelelse
Belkin lancerer syv nye skærmbeskyttere, der er udviklet med proprietær Nano-Titan-teknologi for øget styrke mod daglige fald og ridser Et Wear and Tear-program skaber ro i sindet for forbrugere, der ønsker at udskifte deres produkter Forbrugerne kan nu personalisere deres skærmbeskyttere med Screen Skinz Belkin, et førende mærke inden for forbrugerelektronik i over 40 år, annoncerer i dag en ny klasse af løsninger til skærmbeskyttelse, et strategisk partnerskab og et helt nyt wear-and-tear-program, der styrker virksomhedens engagement i at beskytte enheder og give forbrugerne tryghed. Lanceringen omfatter syv nye skærmbeskyttere, et partnerskab med ScreenSkinz vedrørende personalisering, og et program til udskiftning af skærmbeskyttere beregnet til at give brugerne varig ro i sindet og sikre, at de produkter, de elsker, forbliver trygge, sikre og i den bedste form. Mød ScreenForce Titan-serien: Det ultimative inden for fuldskærmsbeskyttelse Titan SmartShield Titan SmartShield fungerer
Belkin præsenterer næste generation af opladere, strømtilbehør til gaming og meget mere på CES 20264.1.2026 18:00:00 CET | Pressemeddelelse
Belkin lancerer nye trådløse Qi2-opladere, powerbanks med høj kapacitet, kraftfulde hubs samt et opladningsetui til Nintendo Switch 2, der får debut på CES 2026 Belkin, et førende mærke inden for forbrugerelektronik i over 40 år, annoncerede i dag en ny serie af tilbehør, der er designet til at styrke, beskytte og forbedre den måde, folk arbejder, leger og er forbundet på. Den nye kollektion, som debuterer på CES 2026, omfatter avancerede powerbanks, Qi2 25 W trådløse opladere, en trådløs HDMI-dongle til problemfri deling af indhold og et opladningsetui af næste generation til Nintendo Switch 2. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260104854623/da/ Belkin unveils new products at CES 2026 Gaming Charging Case Pro til Nintendo Switch 2 (model ENA003) Udviklet til den ultimative gamingoplevelse på farten leverer Pro-etuiet strøm, beskyttelse og mobilitet samlet i én førsteklasses løsning. En udtagelig powerbank på 1
SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement4.1.2026 16:13:00 CET | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court’s interlocutory order governing the Company’s board composition and corporate actions pending trial, and announced the engagement of Zhonghua Certified Public Accountants LLP (“Zhonghua”), an affiliate of the global accounting network UHY International, as the Company’s independent auditor and registered public accounting firm. Update on Antigua High Court Order Further to the order issued by the Antigua High Court (the “Court”) previously disclosed by the Company in a press release dated December 17, 2025, the Court has updated its order to provide that directors Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Dr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Weidong Yin (collectively, the “Board”), will comprise the Board of the Company until the trial liste
Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report4.1.2026 16:00:00 CET | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”), stating that the Company was not in compliance with Nasdaq’s Listing Rule 5250(c)(2) since the Company did not timely file a Form 6-K containing an interim balance sheet and income statement as of the end of its second quarter of year 2025. As previously disclosed, the Company received a delisting determination letter (the “Staff Determination”) from Nasdaq in November 2025. The Company requested a hearing before the Nasdaq Hearings Panel to appeal the Staff Determination on November 19, 2025. Nasdaq has informed the Company that the Nasdaq Hearings Panel will also consider the matter addressed in the Notification Letter at a hearing scheduled for January 8, 2026 at which the Company has been invited to present
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom